ValuEngine upgraded shares of Alliqua BioMedical, Inc. (NASDAQ:ALQA) from a sell rating to a hold rating in a report issued on Friday, October 6th.
A number of other research firms have also weighed in on ALQA. HC Wainwright decreased their target price on shares of Alliqua BioMedical from $25.00 to $15.00 and set a buy rating on the stock in a research note on Tuesday, July 4th. Zacks Investment Research raised shares of Alliqua BioMedical from a hold rating to a buy rating and set a $5.00 target price on the stock in a research note on Tuesday, August 15th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Alliqua BioMedical presently has a consensus rating of Buy and an average price target of $11.25.
Alliqua BioMedical (NASDAQ ALQA) opened at 3.0425 on Friday. The stock’s 50 day moving average price is $3.33 and its 200-day moving average price is $3.63. The stock’s market cap is $15.24 million. Alliqua BioMedical has a 12 month low of $2.30 and a 12 month high of $8.50.
Alliqua BioMedical (NASDAQ:ALQA) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.40) by $0.50. The company had revenue of $5.52 million for the quarter, compared to the consensus estimate of $5.01 million. Alliqua BioMedical had a negative return on equity of 107.24% and a negative net margin of 185.30%. The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period last year, the firm earned ($2.20) EPS. Analysts anticipate that Alliqua BioMedical will post ($3.55) EPS for the current fiscal year.
WARNING: This article was first published by BBNS and is the property of of BBNS. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://baseballnewssource.com/markets/valuengine-upgrades-alliqua-biomedical-inc-alqa-to-hold/1703001.html.
Several hedge funds and other institutional investors have recently made changes to their positions in ALQA. Perceptive Advisors LLC increased its holdings in shares of Alliqua BioMedical by 120.3% during the 1st quarter. Perceptive Advisors LLC now owns 4,233,951 shares of the company’s stock worth $2,136,000 after buying an additional 2,312,000 shares during the last quarter. Sabby Management LLC increased its holdings in shares of Alliqua BioMedical by 93.7% during the 1st quarter. Sabby Management LLC now owns 2,131,050 shares of the company’s stock worth $1,076,000 after buying an additional 1,030,652 shares during the last quarter. KCG Holdings Inc. increased its holdings in Alliqua BioMedical by 777.7% in the 1st quarter. KCG Holdings Inc. now owns 525,077 shares of the company’s stock valued at $265,000 after purchasing an additional 465,256 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Alliqua BioMedical by 54.2% in the 1st quarter. Renaissance Technologies LLC now owns 632,800 shares of the company’s stock valued at $319,000 after purchasing an additional 222,400 shares during the last quarter.
About Alliqua BioMedical
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with our FREE daily email newsletter.